

PRESS RELEASE**STALLERGENES MAKES ONE STEP FORWARD
TO THE LAUNCH OF ORALAIR® IN FRANCE**

Antony (France), 30 May 2012 – Stallergenes S.A. (Euronext Paris CAC small) today announces that it has received the favourable opinion granted by the Transparency Committee of the HAS (Higher Health Authority) in France for the registration of Oralair® on the list of specialties that may be reimbursed.

The committee considered that Oralair® offers an improvement in actual medical benefits (ASMR IV) and granted a social security refund rate of 15%. Stallergenes is currently in price negotiation with the French authorities. Oralair®'s unique characteristic is to be administered intermittently according to a pre-and co-seasonal protocol. This protocol schedules treatment for only 5 months a year.

“I am looking forward to the forthcoming market launch in France: Oralair® offers specific patient benefits and the feedback from other markets where we launched the product is very encouraging. I am therefore confident that these benefits will be recognized during the price discussions,” stated Roberto Gradnik, Chief Executive Officer of Stallergenes.

Stallergenes' sublingual immunotherapy tablet is now marketed in 14 European countries: Austria, Belgium, Bulgaria, the Czech Republic, Germany, Ireland, Italy, the Netherlands, Poland, Romania, Slovakia, Slovenia, Spain and Switzerland. Early feedback from markets where the product is being launched is very encouraging, including in markets dominated by the subcutaneous route, such as Switzerland. In other European markets in which the product has been granted a marketing authorization, assessments are on-going on price and the level of reimbursement.

Oralair® also continues to expand beyond the borders of Europe. The tablet has recently been launched in Australia and New Zealand. Following the granting of market authorizations in Argentina and Russia, Stallergenes is preparing to launch Oralair® in these two countries with strong potential. Having been granted authorization to market in Canada, Oralair® is the first immunotherapy tablet to be registered on the North American continent and will be introduced soon in this market.

ABOUT ORALAIR®

Oralair® is a sublingual immunotherapy tablet consisting of five purified and calibrated pollen extracts corresponding to the epidemiological characteristics of patient exposure: rye grass (*Lolium perenne*), meadow grass (*Poa pratensis*), timothy grass (*Phleum pratense*), cocksfoot (*Dactylis glomerata*) and sweet vernal grass (*Anthoxanthum odoratum*).

Oralair® is indicated for the treatment of seasonal grass pollen allergic rhinitis with or without conjunctivitis in patients from 5 years of age, confirmed by clinically relevant symptoms, a positive cutaneous test and/or a positive titre of the specific IgE, who have not adequately responded to, or tolerated, conventional pharmacotherapy. To provide a response that is tailored to patients' needs, Oralair® is administered intermittently according to a pre-and co-seasonal protocol. This protocol schedules treatment for only 5 months a year.

The subject of four clinical phase III studies involving over 1,800 patients in Europe, Oralair® offers an indisputable level of proof. It has also been the subject of a clinical phase III study on adults in the United States, the results of which were consistent with the results achieved in Europe.

ABOUT STALLERGENES

Stallergenes is a European biopharmaceutical company specialised in the treatment by allergen immunotherapy of allergy related respiratory diseases, such as severe rhinoconjunctivitis and rhinitis, as well as allergic asthma. The seventh largest pharmaceutical company in France and the leader in sublingual immunotherapy treatment, Stallergenes devotes almost 20% of its gross turnover to Research & Development and is actively involved in the development of a new therapeutic class, sublingual immunotherapy tablets. In 2011, the company had sales of €235 million and more than 500,000 patients were treated with Stallergenes products.

Euronext Paris (Compartment B)
CAC small
ISIN code: FR0000065674
Reuters code: GEN.PA
Bloomberg code: GEN.FP



For further financial information, please visit our website: <http://finance.stallergenes.com>

Forward-looking statements related to Stallergenes

This press release may contain forward-looking statements, including forecasts of future revenue and operating profit as well as expected business-related events. Such statements are based upon the current beliefs and expectations of Stallergenes' management and are subject to risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, changes in competitive factors and reliance on suppliers. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

Contacts

Roberto Gradnik, Chief Executive Officer
Tel. +33 1 55 59 20 04

Investor and Analyst Relations

Christian Thiry, Chief Financial Officer
Tel: +33 1 55 59 20 95
e-mail: investorrelations@stallergenes.fr

Pavie Finance: Lucile de Fraguier
Tel: +44 208 248 2793
e-mail: contact@pavie-finance.com

Stallergenes Press Relations

Lise Lemonnier, Communication Director
Tel: + 33 1 55 59 20 96
e-mail: llemonnier@stallergenes.fr

Chandler Chicco Agency: Bahar Turkoglu
Tel: + 33 1 41 43 02 27
e-mail: bturkoglu@ccapr.com